Decoy Therapeutics Inc. Cash Flow-to-Debt Ratio
Decoy Therapeutics Inc. cash flow-to-debt ratio. Decoy Therapeutics Inc. (DCOY) has a Cash Flow-to-Debt Ratio of -0.57x as of June 2026, meaning its operating cash flow of $-2.65 Million could theoretically repay -1% of its total liabilities ($4.68 Million) in one year. See financial flexibility index of Decoy Therapeutics Inc. to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Decoy Therapeutics Inc. (2014–2025)
Cash flow-to-debt ratio of Decoy Therapeutics Inc. from 2014 to 2025. Historical debt coverage capacity for Decoy Therapeutics Inc. across 12 annual periods. Also explore DCOY year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Decoy Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2014–2025)
Decoy Therapeutics Inc. cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Decoy Therapeutics Inc.. For the full cash flow conversion analysis, see Decoy Therapeutics Inc. (DCOY) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.93x | $-4.83 Million | $5.17 Million | ▲ +68.8% |
| 2024 | -2.99x | $-4.53 Million | $1.51 Million | ▲ +69.7% |
| 2023 | -9.89x | $-12.85 Million | $1.30 Million | ▼ -139.7% |
| 2022 | -4.12x | $-17.60 Million | $4.27 Million | ▲ +14.6% |
| 2021 | -4.83x | $-10.20 Million | $2.11 Million | ▼ -30.0% |
| 2020 | -3.72x | $-10.31 Million | $2.77 Million | ▼ -6.4% |
| 2019 | -3.49x | $-11.58 Million | $3.31 Million | ▲ +83.6% |
| 2018 | -21.32x | $-23.60 Million | $1.11 Million | ▼ -352.7% |
| 2017 | -4.71x | $-27.72 Million | $5.89 Million | ▲ +42.7% |
| 2016 | -8.22x | $-32.05 Million | $3.90 Million | ▼ -14.1% |
| 2015 | -7.21x | $-20.75 Million | $2.88 Million | ▼ -4285.6% |
| 2014 | -0.16x | $-6.93 Million | $42.15 Million | — |